Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ACP-01
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Mcgill University Health Centre
Deal Size : $0.2 million
Deal Type : Funding
Details : The funding will be used to complete a phase II double blind randomized clinical trial of ACP-01, an autologous angiogenic cell precursor, as a treatment of ischemic cardiomyopathy at the McGill University Health Centre.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : ACP-01
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Mcgill University Health Centre
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : ACP-01
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ACP-01 in Patients With Critical Limb Ischemia
Details : ACP-01 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Limb-Threatening Ischemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 16, 2015
Lead Product(s) : ACP-01
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
